Subtype
Gastric Adenocarcinoma
CI-CAN-00005355STADExplore in graph →
137 active trials3 approved drugs22 evidence items
Loading cancer entity…
Subtype
CI-CAN-00005355STADExplore in graph →
Clinical trials
447 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (52)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06203600 | Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial | recruiting | Phase 2 / Phase 3 | 224 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04248452 | Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body | active not recruiting | Phase 3 | 314 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 14, 2026 |
| clinicaltrials |
| NCT05482516 | Evaluating Novel Therapies in ctDNA Positive GI Cancers(MRD-GI) | recruiting | Phase 3 | 20 | Georgetown UniversityOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06764875 | A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer | recruiting | Phase 3 | 840 | AstraZenecaINDUSTRY | 28 | Sep 11, 2026 | clinicaltrials |
| NCT07673887 | A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer | recruiting | Phase 3 | 570 | Astellas Pharma Global Development, Inc.INDUSTRY | 3 | Sep 11, 2026 | clinicaltrials |
| NCT05677490 | mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma | recruiting | Phase 3 | 382 | Alliance for Clinical Trials in OncologyOTHER | 2 | Sep 3, 2026 | clinicaltrials |
| NCT01882933 | D2 Resection and HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) in Locally Advanced Gastric Carcinoma(GASTRICHIP) | completed | Phase 3 | 367 | Hospices Civils de LyonOTHER | 2 | Aug 24, 2026 | clinicaltrials |
| NCT07001748 | Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity(STOPGAP II) | recruiting | Phase 2 / Phase 3 | 148 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07603349 | Adaptive Adjuvant Therapy After Neoadjuvant Therapy and Gastrectomy for Gastric or Gastroesophageal Junction Adenocarcinoma | not yet recruiting | Phase 2 / Phase 3 | 405 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT06532006 | A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer | recruiting | Phase 3 | 550 | Shanghai Henlius BiotechINDUSTRY | 17 | Feb 27, 2026 | clinicaltrials |
| NCT07332533 | A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer | not yet recruiting | Phase 2 / Phase 3 | 490 | Shanghai JMT-Bio Inc.INDUSTRY | 0 | Jan 12, 2026 | clinicaltrials |
| NCT03042169 | Surgical Resection Plus Chemotherapy Versus Chemotherapy Alone in Oligometastatic Stage IV Gastric Cancer(SURGIGAST) | terminated | Phase 3 | 6 | University Hospital, LilleOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT07029269 | Feasibility of Enhanced Recovery After Surgery Without Prophylactic Abdominal Drainage Tubes After Laparoscopic Distal Gastrectomy For Gastric Cancer | recruiting | Phase 3 | 454 | Zuoyi JiaoOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT07103668 | A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients | recruiting | Phase 3 | 150 | Suzhou Immunofoco Biotechnology Co., LtdINDUSTRY | 1 | Oct 23, 2025 | clinicaltrials |
| NCT07018661 | [18F]F-FAPI PET/CT and Laparoscopy in Staging Advanced Gastric Cancer(PLASTIC-3) | recruiting | Phase 2 / Phase 3 | 250 | Leiden University Medical CenterOTHER | 1 | Aug 27, 2025 | clinicaltrials |
| NCT05002127 | A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) | active not recruiting | Phase 2 / Phase 3 | 127 | ALX Oncology Inc.INDUSTRY | 12 | Aug 7, 2025 | clinicaltrials |
| NCT04082364 | Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer(MAHOGANY) | completed | Phase 2 / Phase 3 | 82 | MacroGenicsINDUSTRY | 9 | Jun 8, 2025 | clinicaltrials |
| NCT06028737 | Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer(OCTASUR) | recruiting | Phase 2 / Phase 3 | 150 | Ukrainian Society of Clinical OncologyOTHER | 2 | May 6, 2025 | clinicaltrials |
| NCT04032119 | RCT of Gastric ESD With or Without Epineprhine Added Solution | completed | Phase 3 | 800 | Chinese University of Hong KongOTHER | 4 | May 4, 2025 | clinicaltrials |
| NCT04499924 | Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer(MOUNTAINEER-02) | completed | Phase 2 / Phase 3 | 17 | Seagen Inc.INDUSTRY | 6 | Jan 22, 2025 | clinicaltrials |
| NCT02407119 | Effects of H. Pylori Eradication on the Gastric Preneoplastic Lesion and Neoplasm After ESD | active not recruiting | Phase 3 | 470 | National Cancer Center, KoreaOTHER_GOV | 1 | Nov 9, 2023 | clinicaltrials |
| NCT05813015 | Study of Comparing of With and Without Sequential Therapy of S-1 | recruiting | Phase 3 | 70 | Zhejiang UniversityOTHER | 1 | Apr 14, 2023 | clinicaltrials |
| NCT02494583 | Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062) | completed | Phase 3 | 763 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 13, 2023 | clinicaltrials |
| NCT03042611 | A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer(ANGEL) | completed | Phase 3 | 460 | Elevar TherapeuticsINDUSTRY | 12 | Jul 8, 2022 | clinicaltrials |
| NCT02898077 | A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer | completed | Phase 3 | 440 | Eli Lilly and CompanyINDUSTRY | 4 | Jun 14, 2022 | clinicaltrials |
| NCT02370498 | A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061) | completed | Phase 3 | 592 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 6, 2022 | clinicaltrials |
| NCT02314117 | A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer(RAINFALL) | completed | Phase 3 | 645 | Eli Lilly and CompanyINDUSTRY | 20 | Aug 26, 2021 | clinicaltrials |
| NCT02545504 | Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma(GAMMA-1) | completed | Phase 3 | 432 | Gilead SciencesINDUSTRY | 16 | May 26, 2020 | clinicaltrials |
| NCT02144727 | A Clinical Trial of D1+ Versus D2 Distal Gastrectomy for Stage IB & II Advanced Gastric Cancer(ADDICT) | unknown | Phase 3 | 1,880 | National Cancer Center, KoreaOTHER_GOV | 1 | Apr 20, 2016 | clinicaltrials |
| NCT02512380 | Neoadjuvant SLOT Versus SOX in Patients With Locally Advanced, Resectable Gastric/Esophagogastric Junction (EGJ) Cancer | unknown | Phase 3 | 380 | Chinese Academy of Medical SciencesOTHER | 1 | Aug 10, 2015 | clinicaltrials |
| NCT02219529 | Magnetic-controlled Capsule Endoscopy vs. Gastroscopy for Detection of Gastric Diseases(MCE) | completed | Phase 3 | 350 | Changhai HospitalOTHER | 1 | Jul 21, 2015 | clinicaltrials |
| NCT01989858 | ITACA-S2 (Intergroup Trial in Adjuvant Chemotherapy for Adenocarcinoma of the Stomach)(ITACA-S2) | terminated | Phase 3 | 1,180 | Mario Negri Institute for Pharmacological ResearchOTHER | 1 | Jan 29, 2015 | clinicaltrials |
| NCT02240524 | Efficacy of HIPEC in the Treatment of Patients With Locally Advanced Gastric Cancer(HIPEC) | unknown | Phase 3 | 582 | Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityOTHER | 1 | Sep 15, 2014 | clinicaltrials |
| NCT01283217 | Docetaxel and S1 (DS) Versus S1 and Cisplatin (SP) in Curatively Resected Stage IIIB/IV Gastric Cancer | unknown | Phase 3 | 166 | Yonsei UniversityOTHER | 1 | Jun 4, 2013 | clinicaltrials |
| NCT01583361 | SOX Regimen as Neoadjuvant Chemotherapy for AJCC Stage II-III Gastric Cancer(RESONANCE) | unknown | Phase 3 | 772 | Lin ChenOTHER | 1 | Apr 24, 2012 | clinicaltrials |
Data updated 14 hours agoSource updated Sep 29, 2026source: clinicaltrials